Articles by Ajai Chari, MD
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Ajai Chari, MD, described findings from the MonumenTAL-1 study on talquetamab in patients with myeloma.
The panel gives their opinions on vaccine strategies for patients with myeloma receiving bispecifics.
The panel discusses optimal dosing for teclistamab.
Dr. Martin asks Dr. Chari to provide insights on adverse event management with talquetamab.
The panel continues the conversation around toxicity management for bispecific agents.
The panel addresses side effects that are commonly seen in patients receiving bispecifics.
The panel discusses their personal experience with bispecifics-related REMS programs.
The panel discusses where they think bispecifics have "the best role" in the myeloma treatment paradigm.
The panel provided insights on how they determine whether to give a patient with myeloma CAR T-cell therapy or a bispecific.
The approval of the bispecific antibody is based upon data from the MonumenTAL-1 trial.
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.